On Sep.11, 2019, Shenzhen International Biotech Summit (Biotech 2019) was hosted in Shenzhen Convention and Exhibition Center.
During the summit, the "2019 Shenzhen top 20 leading biotech companies list" was published by KPMG China and Shenzhen National High-Tech Industry Innovation Center in order to boost the high quality development of biomedicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), and promoted the combination among enterprises and capital. Dymind was selected as one of the “Shenzhen top 20 leading biotech companies” with its outstanding corporate strength and brand value, and won full recognition and high praise in the industry.
Dymind has been unanimously recognized by the expert panel in the six dimensions during the review process. As the professional hematology analyzer solution innovator, Dymind insists on innovation leading and deeply ploughing into the subdivided field of hematology analyzer, focusing on testing requirements. Combining with excellent R&D teams, Dymind has innovatively solved a series of clinical pain points, bringing users more intelligent, efficient and accurate usage experience has experienced a rapid development during the last six years, from the development and launch of first product, to the launch of 5-part + CRP hematology analyzer, 3-part & 5-part hematology analyzer, and to 5-part + CRP combined with autoloader for capillary blood. Dymind insists the R&D as core driver, and invests more than 20% of its income in the new product development every year. Dymind rank No.2 in the hematology analyzer market, and the product have been exported to more than 100 countries.
Dymind was selected as one of the top 20 leading biotechnology enterprises in Shenzhen, and got the expert jury and the society’s affirmation. With integared approach to innovative products, Dymind will break through the conventional process, to define the precise and efficient inspection standards.